Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Linear Formula:
Pt(NH3)2Cl2
CAS Number:
Molecular Weight:
300.05
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
EC Number:
239-733-8
MDL number:
grade
pharmaceutical primary standard
API family
cisplatin
manufacturer/tradename
EDQM
mp
270 °C (lit.)
application(s)
pharmaceutical (small molecule)
format
neat
SMILES string
N.N.Cl[Pt]Cl
InChI
1S/2ClH.2H3N.Pt/h2*1H;2*1H3;/q;;;;+2/p-2
InChI key
LXZZYRPGZAFOLE-UHFFFAOYSA-L
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets, has been developed and issued under the Authority of the Issuing Pharmacopoeia.
For further information and support please go to the website of the issuing Pharmacopoeia.
For further information and support please go to the website of the issuing Pharmacopoeia.
Application
This European Pharmacopoeia reference standard is intended for use only as specifically prescribed in the European Pharmacopoeia. Their suitability for any other use is not guaranteed and is the sole responsibility of the user. This standard is not intended for human or animal use.
Established for the preparation of the below-given solutions as per European Pharmacopoeia:
Established for the preparation of the below-given solutions as per European Pharmacopoeia:
- Reference solutions in the identification using infrared absorption spectroscopy and thin-layer chromatography, testing of related substances, and assay using liquid chromatography (General text 2.2.29) of cisplatin, according to the monograph 0599
- Reference solution (b) for the testing of related substances in carboplatin using liquid chromatography (General text 2.2.29), according to the monograph 1081
Biochem/physiol Actions
Potent platinum-based antineoplastic agent. Forms cytotoxic adducts with the DNA dinucleotide d(pGpG), inducing intrastrand cross-links.
Packaging
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
Other Notes
Sales restrictions may apply.
Still not finding the right product?
Explore all of our products under Cisplatin
signalword
Danger
target_organs
Respiratory system
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Hazard Classifications
Acute Tox. 2 Oral - Carc. 1B - Eye Irrit. 2 - Muta. 1B - Repr. 1B - Resp. Sens. 1 - Skin Irrit. 2 - Skin Sens. 1 - STOT SE 3
Storage Class
6.1B - Non-combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Cisplatin
European Pharmacopoeia Commission and European Directorate for the Quality of Medicines & Healthcare
European pharmacopoeia, 2231-2232 (2009)
Michael F Milosevic et al.
International journal of cancer, 135(7), 1692-1699 (2013-08-02)
Radiotherapy (RT) with concurrent cisplatin (CRT) is standard treatment for locally advanced cervical cancer. However, not all patients benefit from the addition of cisplatin to RT alone. This study explored the value of pretreatment tumor interstitial fluid pressure (IFP) and
James Chih-Hsin Yang et al.
The Lancet. Oncology, 16(2), 141-151 (2015-01-16)
We aimed to assess the effect of afatinib on overall survival of patients with EGFR mutation-positive lung adenocarcinoma through an analysis of data from two open-label, randomised, phase 3 trials. Previously untreated patients with EGFR mutation-positive stage IIIB or IV
Global Trade Item Number
| SKU | GTIN |
|---|---|
| C2210000 | 04061833475386 |